<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65561">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054338</url>
  </required_header>
  <id_info>
    <org_study_id>L00070 IN 303 B0</org_study_id>
    <secondary_id>2006-001139-23</secondary_id>
    <nct_id>NCT02054338</nct_id>
  </id_info>
  <brief_title>A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer</brief_title>
  <acronym>VICTORIA</acronym>
  <official_title>Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Peru: General Directorate of Pharmaceuticals, Devices, and Drugs</authority>
    <authority>Portugal: INFARMED, National Authority of Medicines and Health Products, IP</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of vinflunine and gemcitabine in advanced breast cancer in comparison to
      paclitaxel and gemcitabine is based on the following points: the significant antitumour
      activity of vinflunine in metastatic breast cancer (MBC) as single agent after
      anthracycline-taxane exposure and recent phase I study results of the vinflunine plus
      gemcitabine is at least additive and both drugs have a distinct mechanism of action; since
      taxanes have been approved in the adjuvant setting and are widely used in the treatment of
      early breast cancer it is worthwhile to assess new combination chemotherapy regimens as
      first line therapy for metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Every 6 weeks until disease progression</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Every 6 months after disease progression</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate &amp; Disease Control Rate</measure>
    <time_frame>Every 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile</measure>
    <time_frame>Every 3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collection and grading of reported adverse events and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Every 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>vinflunine plus gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel plus gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinflunine 320 mg/m² as a 20-minute infusion on day 1 of each cycle  repeated every 3 weeks gemcitabine 1000 mg/m² IV on day 1 and 8 repeated every 3 weeks</intervention_name>
    <arm_group_label>vinflunine plus gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinflunine plus gemcitabine</intervention_name>
    <description>320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks</description>
    <arm_group_label>vinflunine plus gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel plus gemcitabine</intervention_name>
    <description>paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1</description>
    <arm_group_label>paclitaxel plus gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients

          -  18 years or older but less than 75 years old

          -  histologically/cytologically confirmed breast cancer

          -  documented locally recurrent or metastatic breast cancer

          -  HER-2 negative or unknown

          -  prior neo- and/or adjuvant anthracycline-based chemotherapy

          -  measurable or non-measurable disease according to Response Evaluation Criteria In
             Solid Tumors (RECIST) 1.0

          -  adequate haematological, hepatic and renal functions

          -  ECG without any clinically relevant abnormality

        Exclusion Criteria:

          -  known or clinical evidence of brain metastases or leptomeningeal involvement

          -  history of  second primary malignancy

          -  patients having as sole tumour lesion: malignant effusion, lymphangitis, cystic
             lesion, bone lesion, and any other lesion not assessed by imaging techniques or
             colour photography

          -  pre-existing motor/ensory grade &gt; 1 peripheral neuropathy

          -  prior therapy with vinca alkaloids and/or gemcitabine

          -  history of severe hypersensitivity to vinca alkaloids and/or gemcitabine or
             contraindication to any of these drugs

          -  pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
